×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
TXMD – therapeuticsmd, inc. (US:AMEX)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
TXMD
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
4/10
04:11 pm
txmd
TherapeuticsMD, Inc. (NASDAQ: TXMD) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
High
Report
TherapeuticsMD, Inc. (NASDAQ: TXMD) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
4/1
05:27 pm
txmd
TherapeuticsMD, Inc. (NASDAQ: TXMD) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
Neutral
Report
TherapeuticsMD, Inc. (NASDAQ: TXMD) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
3/30
07:20 am
txmd
TherapeuticsMD Full Year 2024 Earnings: US$0.20 loss per share (vs US$0.74 loss in FY 2023) [Yahoo! Finance]
Low
Report
TherapeuticsMD Full Year 2024 Earnings: US$0.20 loss per share (vs US$0.74 loss in FY 2023) [Yahoo! Finance]
3/27
04:23 pm
txmd
TherapeuticsMD Announces Full Year 2024 Financial Results [Yahoo! Finance]
Medium
Report
TherapeuticsMD Announces Full Year 2024 Financial Results [Yahoo! Finance]
3/27
04:05 pm
txmd
TherapeuticsMD Announces Full Year 2024 Financial Results
Medium
Report
TherapeuticsMD Announces Full Year 2024 Financial Results
1/14
02:05 am
txmd
TherapeuticsMD, Inc. (NASDAQ: TXMD) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
Medium
Report
TherapeuticsMD, Inc. (NASDAQ: TXMD) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
4/10
04:30 pm
txmd
Form 4 TherapeuticsMD, Inc. For: Apr 09 Filed by: Walker Marlan D
High
Report
Form 4 TherapeuticsMD, Inc. For: Apr 09 Filed by: Walker Marlan D
4/9
06:31 am
txmd
Form 8-K TherapeuticsMD, Inc. For: Apr 08
Low
Report
Form 8-K TherapeuticsMD, Inc. For: Apr 08
3/27
04:50 pm
txmd
Form 10-K TherapeuticsMD, Inc. For: Dec 31
Medium
Report
Form 10-K TherapeuticsMD, Inc. For: Dec 31
3/27
04:31 pm
txmd
Form 8-K TherapeuticsMD, Inc. For: Mar 27
Medium
Report
Form 8-K TherapeuticsMD, Inc. For: Mar 27
2/20
09:08 pm
txmd
Form 4 TherapeuticsMD, Inc. For: Feb 18 Filed by: Collins Cooper C.
High
Report
Form 4 TherapeuticsMD, Inc. For: Feb 18 Filed by: Collins Cooper C.
2/20
09:08 pm
txmd
Form 4 TherapeuticsMD, Inc. For: Feb 18 Filed by: Naughton Gail K
High
Report
Form 4 TherapeuticsMD, Inc. For: Feb 18 Filed by: Naughton Gail K
2/20
09:08 pm
txmd
Form 4 TherapeuticsMD, Inc. For: Feb 18 Filed by: Thompson Tommy G
High
Report
Form 4 TherapeuticsMD, Inc. For: Feb 18 Filed by: Thompson Tommy G
2/20
09:07 pm
txmd
Form 4 TherapeuticsMD, Inc. For: Feb 18 Filed by: Walker Marlan D
High
Report
Form 4 TherapeuticsMD, Inc. For: Feb 18 Filed by: Walker Marlan D
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
4/29
Form 10-K/A TherapeuticsMD, Inc. For: Dec 31
76.0%
3/24 TherapeuticsMD Strengthens Board with Appointment of Industry Leaders 21.6%
8/6 Q2/2019 6/30/2019 EPS -0.230 ZacksConsensus -0.170 ActVsEst (0.060) - Miss 20.9%
1/21 Form SC 13G/A TherapeuticsMD, Inc. Filed by: JPMORGAN CHASE & CO 20.6%
9/25 Form 8-K TherapeuticsMD, Inc. For: Sep 25 13.4%
2/5 TherapeuticsMD Inc (NASDAQ: TXMD) had its "buy" rating re-affirmed by analysts at Noble Financial. They now have a $13.00 price target on the stock. 11.7%
8/14 Form 4 TherapeuticsMD, Inc. For: Aug 12 Filed by: Milligan John C.K. IV 9.6%
12/23 TherapeuticsMD Inc (NASDAQ: TXMD) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock. 8.2%
9/16 Form 8-K TherapeuticsMD, Inc. For: Sep 16 7.9%
2/11 TherapeuticsMD: Inside The Numbers [Seeking Alpha] 6.6%
3/24 TherapeuticsMD Strengthens Board with Appointment of Industry Leaders 21.6%
8/6 Q2/2019 6/30/2019 EPS -0.230 ZacksConsensus -0.170 ActVsEst (0.060) - Miss 20.9%
1/21 Form SC 13G/A TherapeuticsMD, Inc. Filed by: JPMORGAN CHASE & CO 20.6%
9/25 Form 8-K TherapeuticsMD, Inc. For: Sep 25 13.4%
2/5 TherapeuticsMD Inc (NASDAQ: TXMD) had its "buy" rating re-affirmed by analysts at Noble Financial. They now have a $13.00 price target on the stock. 11.7%
8/14 Form 4 TherapeuticsMD, Inc. For: Aug 12 Filed by: Milligan John C.K. IV 9.6%
12/23 TherapeuticsMD Inc (NASDAQ: TXMD) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock. 8.2%
9/16 Form 8-K TherapeuticsMD, Inc. For: Sep 16 7.9%
2/11 TherapeuticsMD: Inside The Numbers [Seeking Alpha] 6.6%
TOP News Decliners
10/23
TherapeuticsMD Announces Estimated Third Quarter 2019 Financial Results
-21.6%
6/11 TherapeuticsMD Inc (NASDAQ: TXMD) had its "outperform" rating re-affirmed by analysts at Cowen Inc. They now have a $9.00 price target on the stock, down previously from $16.00. -20.9%
4/30 TherapeuticsMD Inc (NASDAQ: TXMD) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. -19.4%
5/6 Q1/2019 3/31/2019 EPS -0.160 ZacksConsensus -0.170 ActVsEst 0.010 - Beat -18.1%
3/26 TherapeuticsMD Provides COVID-19-Related Business Update -16.9%
3/16 TherapeuticsMD Provides Business Update on COVID-19 Pandemic -12.5%
8/13 Form 4 TherapeuticsMD, Inc. For: Aug 09 Filed by: Thompson Tommy G -11.9%
2/20 Q4/2019 12/31/2019 EPS -0.190 ZacksConsensus -0.200 ActVsEst 0.010 - Beat -11.2%
8/10 TherapeuticsMD Inc (NASDAQ: TXMD) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. -8.6%
12/2 TherapeuticsMD Inc (NASDAQ: TXMD) is now covered by analysts at Guggenheim. They set a "buy" rating on the stock. -8.3%
6/11 TherapeuticsMD Inc (NASDAQ: TXMD) had its "outperform" rating re-affirmed by analysts at Cowen Inc. They now have a $9.00 price target on the stock, down previously from $16.00. -20.9%
4/30 TherapeuticsMD Inc (NASDAQ: TXMD) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. -19.4%
5/6 Q1/2019 3/31/2019 EPS -0.160 ZacksConsensus -0.170 ActVsEst 0.010 - Beat -18.1%
3/26 TherapeuticsMD Provides COVID-19-Related Business Update -16.9%
3/16 TherapeuticsMD Provides Business Update on COVID-19 Pandemic -12.5%
8/13 Form 4 TherapeuticsMD, Inc. For: Aug 09 Filed by: Thompson Tommy G -11.9%
2/20 Q4/2019 12/31/2019 EPS -0.190 ZacksConsensus -0.200 ActVsEst 0.010 - Beat -11.2%
8/10 TherapeuticsMD Inc (NASDAQ: TXMD) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. -8.6%
12/2 TherapeuticsMD Inc (NASDAQ: TXMD) is now covered by analysts at Guggenheim. They set a "buy" rating on the stock. -8.3%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: